Get the Stockscreener App
3.05
1.29%
0.06
After Hours:
3.04
-0.010
-0.33%
Pepgen Inc stock is traded at $3.05, with a volume of 642.61K.
It is up +1.29% in the last 24 hours and up +34.60% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
See More
Previous Close:
$2.99
Open:
$3
24h Volume:
642.61K
Relative Volume:
0.69
Market Cap:
$211.24M
Revenue:
-
Net Income/Loss:
$-77.22M
P/E Ratio:
-1.7396
EPS:
-1.7533
Net Cash Flow:
$-77.27M
1W Performance:
+1.29%
1M Performance:
+34.60%
6M Performance:
-55.40%
1Y Performance:
+134.77%
1-Day Range:
$2.93
$3.08
1-Week Range:
$2.80
$3.14
52-Week Range:
$1.13
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
3.05 | 207.09M | 0 | -77.22M | -77.27M | -1.7533 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Guggenheim | Buy |
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
GSA Capital Partners LLP Makes New Investment in PepGen, Inc. $PEPG - MarketBeat
PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PepGen’s DM1 Bet Runs Into An FDA Hold And Dilution Fears - Finimize
PepGen Inc. (PEPG) Slips 1.17% to $2.94 as Biotech Stock Holds Above Key SupportETF Liquidity - dars.gov.et
Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation - Moomoo
PepGen identifies muscle weakness and myotonia as drivers of speech challenges in DM1 - Traders Union
HC Wainwright Has Positive Outlook of PepGen FY2027 Earnings - MarketBeat
Weekly Recap: 12.5/10 mg/kg dose escalation and Q4 2027 cash runway - TradingView
PepGen Inc (PEPG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PepGen Inc. (PEPG) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 8, 2025 Deadline - The National Law Review
PepGen (NASDAQ:PEPG) Posts Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
PepGen Inc. Stock 12‑Month Price Target Cut to $10.19, Implies 323% Upside - TradingView
PepGen Inc (PEPG) Stock News Today - TradingKey
PepGenCash of $117.20 Mln as of June 30, 2 - Moomoo
PepGen Maintained at Buy as Analyst Cites Encouraging DM1 Safety/Efficacy Profile and Keeps $20 Price Target - TipRanks
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $20 - Moomoo
PepGen advances DM1 trial to highest dose cohort - Investing.com
PepGen Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Craig-Hallum Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
PepGen advances DM1 trial to highest dose cohort By Investing.com - Investing.com South Africa
PepGen Advances PGN-EDODM1 Trial and Strengthens Finances - TipRanks
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - BioSpace
PepGen Q2 net loss narrows as expenses fall - TradingView
PepGen Posts $17.8 Million Q2 Loss as Cash Reaches $117.2 Million - Quiver Quantitative
PepGen Inc. 1H 2026: Net loss $(35.6M), EPS $(0.51) — 10-Q Summary - TradingView
PGN-EDODM1 enters top dose group in new PepGen study - Traders Union
BRIEF-PepGen Q2 EPS USD -0.26 - TradingView
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review - Yahoo Finance
PepGen Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Shareholders of PepGen Should Contact Faruqi & Faruqi Before August 11, 2025 to Discuss Your RightsPEPG - TMX Newsfile
PepGen: PGN-EDODM1 Multisystem Efficacy Potential Supports Buy Rating with Unchanged $20 Price Target - TipRanks
PepGen Inc. Revenue Breakdown – NASDAQ:PEPG - TradingView
PepGen (PEPG) to Post Quarterly Earnings on Thursday - MarketBeat
ADAR1 Capital Management LLC Purchases 1,570,796 Shares of PepGen, Inc. $PEPG - MarketBeat
PepGen Inc (PEPG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PepGen Inc (PEPG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PepGen Inc (PEPG) Cash Flow - TradingKey
1,000,000 Shares in PepGen, Inc. $PEPG Bought by Kalehua Capital Management LLC - MarketBeat
Recover Investment Losses: Levi & Korsinsky Files Class Action Against PepGen Inc. (PEPG) - The National Law Review
PepGen Inc (PEPG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PepGen Inc (PEPG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PepGen Inc (PEPG) Income Statement - TradingKey
PepGen Inc (PEPG) Institutional Confidence - TradingKey
PEPG|PepGen Inc|Price:1.890|Chg%:-0.040 - TradingKey
PepGen Inc (PEPG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PEPG|PepGen Inc|Price:2.950|Chg%:-0.030 - TradingKey
Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today - Stocktwits
PepGen, Inc. (NASDAQ:PEPG) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
PepGen (NASDAQ:PEPG) Shares Down 2.2%What's Next? - MarketBeat
PepGen Inc. (PEPG) Holds Steady at $2.25 as Stock Tests Key Technical LevelsThrowback Trade - dars.gov.et
PepGen Inc. (PEPG) Holds Steady at $2.25 Amid ConsolidationPut Dominated - dars.gov.et
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pepgen Inc Stock (PEPG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STRECK PAUL | EVP, Head of R&D |
Mar 04 '26 |
Sale |
6.23 |
1,879 |
11,709 |
76,226 |
| Donnelly Noel | Chief Financial Officer |
Mar 04 '26 |
Sale |
6.23 |
2,084 |
12,988 |
111,603 |
| McArthur James G | President and CEO |
Mar 04 '26 |
Sale |
6.23 |
5,275 |
32,876 |
296,326 |
| Oxford Science Enterprises plc | Former 10% Owner |
Sep 30 '25 |
Buy |
3.20 |
200,000 |
640,000 |
4,955,388 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Sep 26 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
18,554,273 |
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):